Pages that link to "Q46592356"
Jump to navigation
Jump to search
The following pages link to Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease (Q46592356):
Displaying 28 items.
- Interventions for hirsutism (excluding laser and photoepilation therapy alone) (Q24186393) (← links)
- Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series (Q24645442) (← links)
- Control of ovulation in mice by progesterone receptor-regulated gene networks (Q24657461) (← links)
- Insulin resistance and fertility in polycystic ovary syndrome (Q34480793) (← links)
- Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? (Q34591803) (← links)
- PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice (Q34594089) (← links)
- The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. (Q34994296) (← links)
- State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS) (Q35233754) (← links)
- Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study (Q35813456) (← links)
- Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome (Q35902614) (← links)
- Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments (Q35927890) (← links)
- Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Polycystic Ovary Syndrome (Q36076094) (← links)
- PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility. (Q36465006) (← links)
- The metabolic syndrome in polycystic ovary syndrome (Q36472269) (← links)
- Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? (Q36673559) (← links)
- Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. (Q36690971) (← links)
- Metformin before and during pregnancy and lactation in polycystic ovary syndrome (Q36762451) (← links)
- Thiazolidinediones in dermatology (Q36841072) (← links)
- Peroxisome proliferator-activated receptors: new players in the field of reproduction (Q36903108) (← links)
- New and emerging treatments in dermatology: acne (Q37131011) (← links)
- Initiation of the expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in the rat ovary and the role of FSH. (Q37483119) (← links)
- Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. (Q37953819) (← links)
- Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics? (Q38489705) (← links)
- Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future (Q38641190) (← links)
- Peroxisome proliferator‐activated receptor‐γ and ‐δ polymorphisms in women with polycystic ovary syndrome (Q42907702) (← links)
- Obese Neuronal PPARγ Knockout Mice Are Leptin Sensitive but Show Impaired Glucose Tolerance and Fertility (Q46042235) (← links)
- A Review on the Assessment of the Efficacy of Common Treatments in Polycystic Ovarian Syndrome on Prevention of Diabetes Mellitus (Q47120512) (← links)
- Re: Effects of rosiglitazone on hormonal profile and ovulatory function in Chinese women with polycystic ovary syndrome (Q58029505) (← links)